Skip to content
Peptilyze
CompoundsShopsCompareGuidesMethod
Metabolic research

Mazdutide studies

90 journal papers mention Mazdutide in the title or abstract. Here are the most cited, the latest, and a few facts about the literature.

Studies range from laboratory work to clinical trials. A paper listed here is not an endorsement and says nothing about whether Mazdutide is safe, effective or approved for any use.

Compare Mazdutide prices, from €134.95 →

Papers
90
55 articles, 35 reviews
Earliest paper
2021
Most papers in 2026 (44)
Open access
60%
free to read somewhere
Reviews
39%
of all papers listed

What kind of studies

Of 58 papers in PubMed that mention Mazdutide in the title or abstract, by the study type PubMed records. Categories overlap, so they do not add up to the total.

  • Randomized controlled trials10
  • Other clinical trials0
  • Meta-analyses and systematic reviews10
  • Other reviews27
  • Case reports2
  • Animal studies only1
  • Studies in humans37

Study types are tags assigned by publishers and PubMed indexers; very new papers are often not tagged yet, and a tag is not a quality rating. Retracted papers are excluded. Source: PubMed (NCBI).

Registered clinical studies

Studies on ClinicalTrials.gov that mention Mazdutide in their intervention details. A registration says a study is planned or running, not what it found.

Registered
46
Completed
19
Ongoing or planned
26
Phase 1
13
Phase 2
13
Phase 3
11
  1. Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients

    NCT07897305Not yet recruitingstarted 2026-10-25

  2. ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

    NCT07517042Recruitingstarted 2026-06-10

  3. A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

    NCT06937749Active, not recruitingPhase 2started 2025-06-20

  4. Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity

    NCT07657676RecruitingPhase 4started 2026-09-14

  5. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

    NCT06143956RecruitingPhase 2started 2023-11-17

The five most recently updated studies. See all 46 on ClinicalTrials.gov. Source: ClinicalTrials.gov (U.S. National Library of Medicine). Studies are found by the compound's name, so a few may be about something else.

Papers per year

2021 to 2026, peak 44 papers in a year. The latest year may still be incomplete.

2021: 2 papers2022: 4 papers2023: 3 papers2024: 10 papers2025: 27 papers2026: 44 papers20212026

Where it is published

  1. Diabetes16 papers
  2. Diabetes Obesity and Metabolism6 papers
  3. Frontiers in Endocrinology4 papers
  4. JAMA3 papers
  5. The Lancet Diabetes & Endocrinology3 papers

The papers

ShowAllOpen accessReviews

Most citedName in the title

  1. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight

    Linong Ji, Hongwei� Jiang, Yan Bi et al. · New England Journal of Medicine · 2025

    Randomized trial · Phase 3125 citations

  2. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity

    Linong Ji, Hongwei� Jiang, Zhifeng Cheng et al. · Nature Communications · 2023

    Randomized trial · Phase 2Open access · CC BY118 citationsRead the open copy →

  3. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

    Bo Zhang, Zhifeng Cheng, Ji Chen et al. · Diabetes Care · 2023

    Randomized trial · Phase 2Open access91 citationsRead the open copy →

  4. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial

    Linong Ji, Leili Gao, Hongwei� Jiang et al. · EClinicalMedicine · 2022

    Open access · CC BY83 citationsRead the open copy →

  5. IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study

    Linong Ji, Hongwei� Jiang, Pei An et al. · EClinicalMedicine · 2021

    Open access · CC BY63 citationsRead the open copy →

  6. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes

    Hongwei� Jiang, Shuguang Pang, Yawei Zhang et al. · Nature Communications · 2022

    Randomized trial · Phase 1Open access · CC BY52 citationsRead the open copy →

  7. Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials

    David Lubasi Nalisa, Nelson Cuboia, Eman Ali Dyab et al. · Frontiers in Endocrinology · 2024

    Meta-analysisOpen access · CC BY30 citationsRead the open copy →

  8. Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis

    Wanqing Dong, Jie Bai, Qibin Yuan et al. · EBioMedicine · 2025

    Study in humansOpen access · CC BY-NC-ND28 citationsRead the open copy →

  9. Mazdutide reduces body weight in adults with overweight or obesity: A high‐dose Phase 1 trial

    Shobha Bhattachar, Lai San Tham, Li Yan et al. · Diabetes Obesity and Metabolism · 2025

    Randomized trial · Phase 1Open access · CC BY-NC13 citationsRead the open copy →

  10. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes

    Lixin Guo, Bo Zhang, Xia Xue et al. · Nature · 2025

    Randomized trial · Phase 312 citations

  11. Mazdutide versus placebo in Chinese adults with type 2 diabetes

    Dalong Zhu, Jiajun Zhao, Hanqing Cai et al. · Nature · 2025

    Randomized trial · Phase 312 citations

  12. Mazdutide: First Approval

    Matt Shirley · Drugs · 2025

    Review12 citations

  13. Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial

    Yingying Luo, Hongwei Jiang, Bimin Shi et al. · Contemporary Clinical Trials · 2025

    Study in humans10 citations

  14. 1856-LB: Efficacy and Safety of Mazdutide in Chinese Participants with Overweight or Obesity (GLORY-1)

    Linong Ji, HONGWEI JIANG, Hua Li et al. · Diabetes · 2024

    10 citations

  15. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity

    Leili Gao, H X Jiang, Hanqing Cai et al. · JAMA · 2026

    Randomized trial · Phase 3Open access9 citationsRead the open copy →

  16. 1866-LB: A Phase 2 Study of Mazdutide 9 mg in Chinese Adults with BMI of 30 kg/m2 or more

    HONGWEI JIANG, Linong Ji, YAWEI ZHANG et al. · Diabetes · 2024

    6 citations

  17. 1857-LB: Improvement of Liver Steatosis by Mazdutide in Chinese Participants with Overweight or Obesity—An Exploratory Analysis of GLORY-1

    Linong Ji, HONGWEI JIANG, YAWEI ZHANG et al. · Diabetes · 2024

    5 citations

  18. Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m2 but without diabetes: A phase 2 randomized controlled trial

    Linong Ji, Hongwei Jiang, Zhifeng Cheng et al. · Med · 2026

    Randomized trial · Phase 24 citations

  19. Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non‐Diabetic Adults: A Meta‐Analysis of Randomised Controlled Trials

    Muhammad Hussain Azam, Muhammad Hussain Azam, Khair‐un‐Nisa Azam et al. · Diabetes Obesity and Metabolism · 2026

    Meta-analysis3 citations

  20. Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials

    Hazem Ayesh, Suhail K. Ayesh, Kevin Dean Niswender · American Journal of Therapeutics · 2024

    Meta-analysis3 citations

  21. Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation

    Liangyu Gan, Lengxin Duan, Xueyi Zheng · Pharmaceuticals · 2026

    Open access · CC BY2 citationsRead the open copy →

  22. 306-OR: Mazdutide vs. Placebo as Monotherapy in Patients with Type 2 Diabetes (DREAMS-1)

    Dalong Zhu, Jiajun Zhao, Cai H et al. · Diabetes · 2025

    2 citations

  23. 77-LB: A Novel Glucagon-Like Peptide-1 (GLP-1R) and Glucagon (GCGR) Receptor Dual Agonist, Mazdutide (IBI362), Attenuates Hyperuricemia in Hyperuricemic Rats

    HONGWEI JIANG, YANZHAO ZHANG, YAN SHUANG REN · Diabetes · 2023

    2 citations

  24. Efficacy and Safety of the Dual Glucagon‐Like Peptide‐1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta‐Analysis

    Abul B. M. Kamrul-Hasan, Subhankar Chatterjee, Hamid Ashraf et al. · Diabetes Obesity and Metabolism · 2026

    Meta-analysisOpen access1 citationsRead the open copy →

  25. 1133-OR: Safety, Tolerability, and Pharmacokinetics of Once-Weekly Mazdutide in Chinese Adolescents with Obesity: A Phase 1b Trial

    Chunxiu Gong, XIN NI, Jiajia Chen et al. · Diabetes · 2026

    1 citations

  26. Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes

    Mohammed Abdul Fasi · Expert Opinion on Therapeutic Patents · 2026

    Review1 citations

  27. Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia

    Wenfei Cheng, Zilong Chen, Puyu Li et al. · Frontiers in Endocrinology · 2025

    Case reportOpen access · CC BY1 citationsRead the open copy →

  28. 1616-P: Effect of Mazdutide on MASH Fibrosis—Targeting the Liver–Gut Axis and Microbiome

    Hui Wang, Ling Li · Diabetes · 2025

    1 citations

  29. IDF21-0323 Safety and efficacy of IBI362 (LY3305677) in Chinese patients with T2D: A randomized, placebo-controlled phase 1b study

    Wenli Yang, Hongwei Jiang, T. Yu et al. · Diabetes Research and Clinical Practice · 2022

    Open access1 citationsRead the open copy →

  30. Effectiveness of the Dual GLP-1R/GCGR Agonist Mazdutide in GSD IXc: A Case Report

    陈英英, Xueyu Zhong, Xin Guo et al. · Journal of Clinical Medicine · 2026

    Case reportOpen access · CC BYRead the open copy →

  31. The GLP ‐ 1R / GCGR Dual Agonist Mazdutide Attenuates Liver Steatosis and Decreases Circulating Cholesterol Levels in Mice With Metabolic Dysfunction‐Associated Steatotic Liver Disease

    Lehan Yu, Guangyan Wang, Jingyi Zhang et al. · Diabetes Obesity and Metabolism · 2026

    Open accessRead the open copy →

  32. Comparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials

    Ahmad Hassan, Qurrat Ul Ain Farooq, FNU Parwesh et al. · F1000Research · 2026

    ReviewOpen access · CC BYRead the open copy →

  33. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial

    Stanley H. Hsia, Harold Edward Bays, Liana K. Billings et al. · The Lancet Diabetes & Endocrinology · 2026

    Randomized trial · Phase 2

  34. Mazdutide and the metabolic treatment revolution

    Xianyu Li, Bibo Shao, Min Ruan et al. · Trends Open · 2026

    ReviewOpen access · CC BYRead the open copy →

  35. Efficacy and Safety of Mazdutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials

    Affaf Mahmood, Noor Us Sehar, Aimen Farooq et al. · F1000Research · 2026

    ReviewOpen access · CC BYRead the open copy →

  36. Efficacy and safety of mazdutide vs. dulaglutide in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

    Muhammad Hassan, Muhammad Hussain, Saifullah Khan et al. · Diabetology & Metabolic Syndrome · 2026

    ReviewOpen access · CC BYRead the open copy →

  37. Mazdutide in Asian Obesity: Mechanistic Rationale, Emerging Clinical Evidence, and Relevance to South Asia

    Ahmad Alam, Mohd Salman · Bangladesh Journal of Endocrinology and Metabolism · 2026

    Open access · CC BY-NC-NDRead the open copy →

  38. 1226-OR: Mazdutide vs. Semaglutide in Chinese Adults with Type 2 Diabetes and Obesity (DREAMS-3): A Randomised, Open-Label, Phase 3b Trial

    YINGYING LUO, HONGWEI JIANG, BIMIN SHI et al. · Diabetes · 2026

  39. 1225-OR: Efficacy and Safety of Mazdutide 9 mg in Chinese Adults with Obesity: Results from the Phase 3 GLORY-2 Trial

    Linong Ji, Leili Gao, HONGWEI JIANG et al. · Diabetes · 2026

  40. Mazdutide and Orforglipron—New Evidence in Obesity and Diabetes

    Kishore M. Gadde, Jonanne Talebloo, Steven B. Heymsfield · JAMA · 2026

LatestName in title or abstract

  1. EMERGING PHARMACOLOGICAL STRATEGIES IN OBESITY: FROM GLP-1 AGONISTS THROUGH TRIPLE INCRETIN THERAPY TO AMYLIN ANALOGS – NARRATIVE REVIEW

    Dagmara Laufer, Olga Klimczak, Filip Chodań et al. · Archiv Euromedica · 2026

    ReviewOpen accessRead the open copy →

  2. From Oxyntomodulin to Retatrutide: A Translational Review of Metabolic Polyagonism

    Héctor Iván Saldívar-Cerón, Daniela Maldonado-Trejo, Quetzal Chavez-Castañeda et al. · International Journal of Molecular Sciences · 2026

    Open access · CC BYRead the open copy →

  3. Effectiveness of the Dual GLP-1R/GCGR Agonist Mazdutide in GSD IXc: A Case Report

    陈英英, Xueyu Zhong, Xin Guo et al. · Journal of Clinical Medicine · 2026

    Case reportOpen access · CC BYRead the open copy →

  4. The GLP ‐ 1R / GCGR Dual Agonist Mazdutide Attenuates Liver Steatosis and Decreases Circulating Cholesterol Levels in Mice With Metabolic Dysfunction‐Associated Steatotic Liver Disease

    Lehan Yu, Guangyan Wang, Jingyi Zhang et al. · Diabetes Obesity and Metabolism · 2026

    Open accessRead the open copy →

  5. The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications

    Zhiyu Chen, Ying Zhou, Gang Li et al. · Journal of Diabetes & Metabolic Disorders · 2026

    ReviewOpen accessRead the open copy →

  6. The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction–Associated Steatohepatitis—A Narrative Review with a Translational Focus

    Jamy D. Ard, Jaime P. Almandoz · Obesity Reviews · 2026

    ReviewOpen accessRead the open copy →

  7. Effects of Incretin-Based Pharmacotherapies on Lean Body Mass in Adults With Overweight, Obesity, or Type 2 Diabetes: A Systematic Review With Prespecified Network Meta-Analysis Feasibility Assessment

    Zahi M Alhamad, Naif AlShalhoub, Abdulrahman Al-mana et al. · Cureus · 2026

    ReviewOpen access · CC BYRead the open copy →

  8. The metabolic paradigm shift in gastroenterology and hepatology: Clinical applications of incretin-based co-agonists

    Abdulrahman Ismaiel, Dan Lucian Dumitrascu · Best Practice & Research Clinical Gastroenterology · 2026

    Open access · CC BY-NCRead the open copy →

  9. Efficacy and Safety of Dual GLP ‐1/Glucagon Receptor Agonism in Overweight and Obesity: A Class‐Specific Systematic Review and Meta‐Analysis

    Muhammad Maaz Amjad, Muhammad Mustafa Khan, Fatima Sarwar et al. · Diabetes Obesity and Metabolism · 2026

    ReviewOpen accessRead the open copy →

  10. Glucagon is terug: survodutide opent nieuw hoofdstuk in obesitas en MASLD

    Marcel H.A. Muskiet · Nederlands Tijdschrift voor Diabetologie · 2026

    Open access · CC BY-NC-NDRead the open copy →

  11. Comparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials

    Ahmad Hassan, Qurrat Ul Ain Farooq, FNU Parwesh et al. · F1000Research · 2026

    ReviewOpen access · CC BYRead the open copy →

  12. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial

    Stanley H. Hsia, Harold Edward Bays, Liana K. Billings et al. · The Lancet Diabetes & Endocrinology · 2026

    Randomized trial · Phase 2

  13. Mazdutide and the metabolic treatment revolution

    Xianyu Li, Bibo Shao, Min Ruan et al. · Trends Open · 2026

    ReviewOpen access · CC BYRead the open copy →

  14. Efficacy and Safety of Mazdutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials

    Affaf Mahmood, Noor Us Sehar, Aimen Farooq et al. · F1000Research · 2026

    ReviewOpen access · CC BYRead the open copy →

  15. Renoprotective effects of tubular glucagon receptor activation mediated by V-ATPase

    Hua Qu, Mingyue Xu, Pan Du et al. · Science Advances · 2026

    Study in humansOpen access · CC BY-NCRead the open copy →

  16. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials

    Deshi Chen, Bing Ma, Hao Sun et al. · BMJ Medicine · 2026

    ReviewOpen access · CC BY-NCRead the open copy →

  17. Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon‐Like Peptide‐1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus

    Pamela R. Kushner, Erin D. Michos · Journal of the American Heart Association · 2026

    ReviewOpen access · CC BY1 citationsRead the open copy →

  18. Efficacy and safety of mazdutide vs. dulaglutide in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

    Muhammad Hassan, Muhammad Hussain, Saifullah Khan et al. · Diabetology & Metabolic Syndrome · 2026

    ReviewOpen access · CC BYRead the open copy →

  19. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis

    Kailei Nong, Qingyang Shi, Xinran Xie et al. · BMJ · 2026

    Systematic reviewOpen access · CC BY-NC10 citationsRead the open copy →

  20. Efficacy and Safety of the Dual Glucagon‐Like Peptide‐1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta‐Analysis

    Abul B. M. Kamrul-Hasan, Subhankar Chatterjee, Hamid Ashraf et al. · Diabetes Obesity and Metabolism · 2026

    Meta-analysisOpen access1 citationsRead the open copy →

  21. Mazdutide in Asian Obesity: Mechanistic Rationale, Emerging Clinical Evidence, and Relevance to South Asia

    Ahmad Alam, Mohd Salman · Bangladesh Journal of Endocrinology and Metabolism · 2026

    Open access · CC BY-NC-NDRead the open copy →

  22. 1226-OR: Mazdutide vs. Semaglutide in Chinese Adults with Type 2 Diabetes and Obesity (DREAMS-3): A Randomised, Open-Label, Phase 3b Trial

    YINGYING LUO, HONGWEI JIANG, BIMIN SHI et al. · Diabetes · 2026

  23. 1225-OR: Efficacy and Safety of Mazdutide 9 mg in Chinese Adults with Obesity: Results from the Phase 3 GLORY-2 Trial

    Linong Ji, Leili Gao, HONGWEI JIANG et al. · Diabetes · 2026

  24. Mazdutide and Orforglipron—New Evidence in Obesity and Diabetes

    Kishore M. Gadde, Jonanne Talebloo, Steven B. Heymsfield · JAMA · 2026

  25. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity

    JAMA · 2026

  26. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity

    Leili Gao, H X Jiang, Hanqing Cai et al. · JAMA · 2026

    Randomized trial · Phase 3Open access9 citationsRead the open copy →

  27. 1133-OR: Safety, Tolerability, and Pharmacokinetics of Once-Weekly Mazdutide in Chinese Adolescents with Obesity: A Phase 1b Trial

    Chunxiu Gong, XIN NI, Jiajia Chen et al. · Diabetes · 2026

    1 citations

  28. 2505-P: Mazdutide, a GCGR/GLP-1R Dual Agonist, Alleviates MASH and Liver Fibrosis through Hepatocytes–Hepatic Stellate Cells Cross Talk

    LING FENG ZHANG, HUI WANG, LING LI et al. · Diabetes · 2026

  29. 1733-P: Effect of Mazdutide on Kidney Function in Adults with Obesity or Overweight

    Stanley H. Hsia, Harold Edward Bays, Liana K. Billings et al. · Diabetes · 2026

  30. 1686-P: Dual GLP-1R/GCGR Activation Reprograms Systemic and Hepatic Metabolism to Ameliorate MAFLD

    Danni Gao, QI PAN, LIXIN GUO · Diabetes · 2026

  31. 1693-P: Mazdutide Improves Markers of Insulin Sensitivity in Adults with Obesity without Type 2 Diabetes

    Melissa K. Thomas, Ann Marie Weideman, Tamer Coşkun et al. · Diabetes · 2026

  32. Beyond weight loss: multisystem benefits of obesity medications

    Mesut Savas, Susanne Kuckuck, Mariëtte R. Boon et al. · The Lancet Diabetes & Endocrinology · 2026

    Review4 citations

  33. Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies

    Ioannis G. Lempesis, Μaria Dalamaga · Metabolism Open · 2026

    ReviewOpen access · CC BY8 citationsRead the open copy →

  34. Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m2 but without diabetes: A phase 2 randomized controlled trial

    Linong Ji, Hongwei Jiang, Zhifeng Cheng et al. · Med · 2026

    Randomized trial · Phase 24 citations

  35. Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes

    Mohammed Abdul Fasi · Expert Opinion on Therapeutic Patents · 2026

    Review1 citations

  36. Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non‐Diabetic Adults: A Meta‐Analysis of Randomised Controlled Trials

    Muhammad Hussain Azam, Muhammad Hussain Azam, Khair‐un‐Nisa Azam et al. · Diabetes Obesity and Metabolism · 2026

    Meta-analysis3 citations

  37. Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta‐Analysis of Randomised Controlled Trials

    Ayah Abulehia, Hazem Ayesh, Omar Ayesh et al. · Endocrinology Diabetes & Metabolism · 2026

    ReviewOpen access · CC BY2 citationsRead the open copy →

  38. Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation

    Liangyu Gan, Lengxin Duan, Xueyi Zheng · Pharmaceuticals · 2026

    Open access · CC BY2 citationsRead the open copy →

  39. A new era in reducing obesity and the risk of cardiovascular disease events in preeclampsia

    Ayesha Malik, Rayaz Ahmed Malik · Journal of Hypertension · 2026

    1 citations

  40. Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis

    Zhi Hong Chan, Abdousamad Said Omar, Kieran Gill et al. · Cardiology in Review · 2026

    Review1 citations

Each list shows up to 40 papers.See all 90 on OpenAlex. Source: OpenAlex (CC0), journal articles and reviews with a DOI, retractions excluded, refreshed weekly, last 4 Nov 2026, 08:31 UTC. Papers are listed by their metadata only; follow the links to read them. A license shown on an open copy is the license the publisher or repository states for that copy.